PURPOSE: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. METHODS: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. RESULTS: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. CONCLUSION: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.
PURPOSE: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancerpatients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. METHODS: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancerpatients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. RESULTS: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. CONCLUSION: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.
Entities:
Keywords:
breast cancer; human plasma metabolomics; metabolic profiling; molecular subtypes; personalized medicine
Authors: Sandra Esperanza Díaz-Casas; Jorge Alberto Castilla-Tarra; Esperanza Pena-Torres; Martha Orozco-Ospino; Sara Mendoza-Diaz; Marcela Nuñez-Lemus; Oscar Garcia-Angulo; Mauricio Garcia-Mora; Luis Guzman-AbiSaab; Carlos Lehmann-Mosquera; Javier Angel-Aristizabal; Carlos Duarte-Torres; Juan Carlos Vergel-Martinez Journal: Oncologist Date: 2019-07-25
Authors: Caridad Díaz; Carmen González-Olmedo; Leticia Díaz-Beltrán; José Camacho; Patricia Mena García; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Juan Antonio Marchal; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira Journal: Mol Oncol Date: 2022-04-14 Impact factor: 7.449
Authors: Judith Buentzel; Henry Gerd Klemp; Ralph Kraetzner; Matthias Schulz; Gry Helene Dihazi; Frank Streit; Annalen Bleckmann; Kerstin Menck; Darius Wlochowitz; Claudia Binder Journal: Int J Mol Sci Date: 2021-12-17 Impact factor: 5.923
Authors: Carola Politi; Claudia Fattuoni; Alessandra Serra; Antonio Noto; Silvia Loi; Andrea Casanova; Gavino Faa; Alberto Ravarino; Luca Saba Journal: J Public Health Res Date: 2021-05-25